Hangzhou Tigermed Consulting (HKG:3347) said its directors and controlling shareholders, Ye Xiaoping and Cao Xiaochun, are being investigated in China, according to a Tuesday filing with the Hong Kong bourse.
The clinical trial services provider's shares fell nearly 6% in morning trade on Wednesday.
China's Securities Regulatory Commission launched a probe into Ye and Cao for possible violations regarding information disclosure related to changes in the company's shareholding, the filing said.
Tigermed Consulting said the probe will not affect its day-to-day operations.